{"id":"NCT01281189","sponsor":"Knopp Biosciences","briefTitle":"Phase 3 Study of Dexpramipexole in ALS","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2011-01-21","resultsPosted":"2021-06-07","lastUpdate":"2021-06-07"},"enrollment":942,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Dexpramipexole","otherNames":["KNS-760704","BIIB050"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dexpramipexole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).","primaryOutcome":{"measure":"Composite Assessment of Function and Survival (CAFS) at 12 Months","timeFrame":"12 months","effectByArm":[{"arm":"Placebo","deltaMin":438.84,"sd":null},{"arm":"Dexpramipexole","deltaMin":441.76,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8568"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":82,"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24067398"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":233,"n":468},"commonTop":["FALL","CONSTIPATION","DYSPHAGIA","NAUSEA","RESPIRATORY FAILURE"]}}